Day Zero Diagnostics Presents Direct-From-Blood, Rapid Antimicrobial Susceptibility Testing at ASM Microbe
Day Zero Diagnostics Presents Direct-From-Blood, Rapid Antimicrobial Susceptibility Testing at ASM Microbe
BOSTON, June 17, 2024 /PRNewswire/ -- Day Zero Diagnostics, Inc. (DZD), an infectious disease diagnostics company harnessing the power of whole-genome sequencing and AI to combat the rise of antibiotic-resistant infections, presented three presentations at the 2024 ASM Microbe conference. ASM Microbe is the premier annual conference organized by the American Society of Microbiology and takes place June 13-17, 2024 in Atlanta, GA.
2024年6月17日，美國波士頓/美通社——Day Zero Diagnostics, Inc.（DZD）是一家傳染病診斷公司，利用全基因組測序和人工智能來應對抗擊抗生素耐藥性增強的病原體的威脅。DZD在2024年美國微生物學會（ASM Microbe）會議上做了三次報告。ASM Microbe是美國微生物學會主辦的年度頂級會議，於2024年6月13日至17日在喬治亞洲亞特蘭大市舉行。
Dr. Jason Wittenbach, Director of Data Science at DZD, presented, as part of the "Rapid AST and Diagnostics Methods" session, results of a study demonstrating DZD's ability through Keynome, its machine learning computational platform, to decipher bacterial whole genomes retrieved from patient blood samples and to predict antimicrobial resistance comprehensively and accurately, without the use of culture. In addition, Dr. Wittenbach presented, as part of the symposium "What Will AI Provide to Clinical Microbiology and Public Health in 10 Years", a large-scale research performed in collaboration with UC Irvine, demonstrating concordance of Keynome gAST results from pathogen WGS inputs – with phenotypic AST.
DZD的數據科學董事Jason Wittenbach博士作爲“快速AST和診斷方法”會議的一部分，介紹了DZD的Keynome的研究結果。通過DZD的機器學習計算平台，從患者血樣中獲取細菌全基因組，並在無需培養的情況下全面準確地預測細菌的抗微生物感受性，而Wittenbach博士還作爲“未來10年人工智能將爲臨床微生物學和公共衛生提供什麼”的專題研討會的主講人，介紹了與加州大學爾灣分校合作的大規模研究，展示了在DZD的Keynome的基因組AST（gAST）輸入中展現的抗原（pathogen WGS inputs）的符合性。“與科學家先前確認的抗性基因檢測傳統方法不同，支撐位的機器學習算法通過研究48000多個細菌基因組與450000多個抗感染試驗結果的數據庫，自行推斷出抗性與感受性的關鍵因素，” Wittenbach博士說。
"Unlike traditional approaches for inferring resistance from pathogen genomes that rely on the detection of resistance genes previously identified by scientists, the machine learning algorithms that power Keynome have deduced the drivers of resistance and susceptibility on their own by sifting through a database of over 48,000 bacterial genomes paired with over 450,000 susceptibility test results," said Dr. Wittenbach.
同時，Nicole Billings博士，DZD的實驗室服務和平台擴展高級總監，展示了正在進行的臨床研究可行性階段的結果，展示了DZD的富集過程（Pathovate）能夠直接從血液中恢復臨床病原體基因組以進行整個基因組測序，以及利用機器學習進行細菌或真菌ID和AST預測的新算法（Keynome）。
Also, Dr. Nicole Billings, Sr. Director of Lab Services and Platform Expansion at DZD, presented results from the feasibility phase of an ongoing clinical study demonstrating DZD's enrichment process (Pathovate) capability of recovering clinical pathogen genomes directly from blood for whole genome sequencing, as well as its novel algorithms (Keynome) for bacterial or fungal ID and AST prediction using machine learning.
關於Day Zero Diagnostics總部位於波士頓的Day Zero Diagnostics公司是一家利用全基因組測序和人工智能開創性地開發了一類新的傳染病診斷方法，從臨床樣本中快速鑑別病原物種和抗菌素敏感性譜。Day Zero還推出了一系列使用專有技術的實驗室服務，品牌名爲epiXact，以幫助醫療機構管理感染爆發，調查感興趣的微生物，並做出高影響力的決策。Day Zero Diagnostics成立於2016年，是由來自哈佛大學和馬薩諸塞州綜合醫院的一組臨床醫生和科學家創立的。該公司曾被CARB-X、UCSF Health、美國臨床化學協會、MedTech Innovator、TedMed Hive、HealthTech Arkansas和MassChallenge HealthTech等機構評爲領先的創新者。關注DZD在Twitter上的動態。"
About Day Zero Diagnostics
本新聞稿的來源：Day Zero Diagnostics公司，Inc。
Day Zero Diagnostics, Inc., based in Boston, is pioneering a new class of infectious disease diagnostics using whole-genome sequencing and artificial intelligence to revolutionize how the world fights the growing threat of antimicrobial resistance. The company's mission is to change the way infectious diseases are diagnosed and treated by rapidly identifying both the species and the antimicrobial susceptibility profile of severe infections directly from a clinical sample without the need for a culture. Day Zero also offers a family of lab services under the epiXact brand that utilize proprietary technologies to assist healthcare organizations manage infection outbreaks, investigate organisms of interest, and make high-impact decisions. Day Zero Diagnostics was founded in 2016 by a team of clinicians and scientists from Harvard University and the Massachusetts General Hospital. The company has been recognized as a leading innovator by CARB-X, UCSF Health, American Association of Clinical Chemistry, MedTech Innovator, TedMed Hive, HealthTech Arkansas, and MassChallenge HealthTech. Follow DZD on X (formerly Twitter) and LinkedIn.
Day Zero Diagnostics，Inc。是一家總部位於波士頓的公司，利用全基因組測序和人工智能開拓了一種全新的傳染病診斷方法，革新了全球抗菌素耐藥性增強威脅的抗感染疾病的診斷和治療方式。該公司的使命是通過直接從臨床樣本中快速鑑別嚴重感染的物種和抗微生物敏感性譜，從根本上改變傳染病的診斷和治療方式。Day Zero還在epiXact品牌下提供一系列實驗室服務，利用專有技術幫助醫療機構管理感染爆發，調查感興趣的微生物，並做出高影響力的決策。Day Zero Diagnostics於2016年由哈佛大學和馬薩諸塞州綜合醫院的一組臨床醫生和科學家創立。該公司曾被CARB-X、UCSF Health、美國臨床化學協會、MedTech Innovator、TedMed Hive、HealthTech Arkansas和MassChallenge HealthTech等機構評爲領先的創新者。 本新聞稿所述的研究得到CARB-X的支持。CARB-X爲該項目提供資金，這些資金部分來自美國衛生與公衆服務部管理的戰略準備和響應管理局，生物醫學先進研究和發展局；合同號：75A50122C00028，並獲得來自威爾康基金會（WT224842）和德國教育與研究部的獎項。本新聞稿的內容由作者獨立負責，不代表CARB-X或其任何資助機構的正式觀點。X(前身爲Twitter)以及LinkedIn.
Research reported in this press release is supported by CARB-X. CARB-X's funding for this project is provided in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; under agreement number: 75A50122C00028, and by awards from Wellcome (WT224842) and Germany's Federal Ministry of Education and Research (BMBF). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders.
Day Zero Diagnostics，Inc。
Media contact
媒體聯繫人
SOURCE Day Zero Diagnostics, Inc.
來源：Day Zero Diagnostics, Inc。
譯文內容由第三人軟體翻譯。